We offer ready-to-use probe and primer sets that enable confident and scalable SARS-CoV-2 testing.

We safeguard the integrity of your COVID-19 workflows by manufacturing and shipping oligos in a completely separate and geographically distant facility from positive control production.

We’re the inventor and original source of all the quenching technologies that are cited in the protocols published by WHO

You can rely on our secure, vertically integrated supply chain which allows us to manufacture oligos quickly and at scale

Move quickly with a ready-to-use, out-of-the-box solution for high complexity CLIA labs running the CDC EUA protocol. 

• 

  2019-nCoV CDC-qualified Probe and Primer Kits for SARS-CoV-2

Pick and choose which COVID-19 signatures work best for your lab with individual RUO probes and primers using sequences as designated by Charité and US CDC protocols:

• 

  Charité 2019-nCoV BBQ-650 ValuPanel Reagents

• 

  Charité 2019-nCoV BHQ ValuPanel Reagents

• 

  US CDC 2019-nCoV ValuPanel Reagents

• 

  Yale 2019-nCoV SalivaDirect ValuPanel Reagents

• 

  CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex ValuPanel Reagents

Request probes of your own design using the BHQ technology we invented:

• 

  See all DNA probe formats

LGC SeraCare offer a complete Quality Solution for COVID-19 diagnostic assay validation

AccuPlex™ technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process quality solutions that challenge the entire diagnostic workflow, making them the preferred alternative to infectious materials.

Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance. Products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Negative materials targeting the human RNase P gene are also included.

“We just went ‘live’ with the SARS-CoV-2 assay…I’ve never brought in and validated an assay in 7 days. The LGC SeraCare reference material works perfectly. I needed something other than the assay’s positive control to create a positive assay result before I felt comfortable releasing the assay for patient testing, and your product did the trick.”

Medical Director, Clinical Chemistry Laboratory prominent Boston Academic Medical Hospital

For testing

Confidently meet surging demand with a large-scale, end-to-end testing solution. 

As the need for SARS-CoV-2 testing continues to grow for both diagnostic and screening applications, many organizations are looking to expand or create testing capacity.  For existing diagnostic labs, limited supplies of instruments, reagents and laboratory technologists make getting high volumes of testing done in a timely manner challenging. 

Biosearch Technologies offers fully automated PCR testing technology that is redefining high-throughput for SARS-CoV-2 detection to 35,000 tests per day on a single system. To further enable mass testing, our ultra-high-throughput PCR testing system is capable of processing up to 150,000 tests per day on a single system.